OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
Alessandro Di Federico, Stephanie Alden, James W. Smithy, et al.
Annals of Oncology (2024) Vol. 35, Iss. 10, pp. 902-913
Closed Access | Times Cited: 10
Alessandro Di Federico, Stephanie Alden, James W. Smithy, et al.
Annals of Oncology (2024) Vol. 35, Iss. 10, pp. 902-913
Closed Access | Times Cited: 10
Showing 10 citing articles:
Dual-Enzyme-Instructed Peptide Self-Assembly to Boost Immunogenic Cell Death by Coordinating Intracellular Calcium Overload and Chemotherapy
H. H. Zhang, Yuhan Hu, Yinghao Ding, et al.
ACS Nano (2025) Vol. 19, Iss. 1, pp. 488-503
Closed Access | Times Cited: 1
H. H. Zhang, Yuhan Hu, Yinghao Ding, et al.
ACS Nano (2025) Vol. 19, Iss. 1, pp. 488-503
Closed Access | Times Cited: 1
A facile liquid biopsy assay for highly efficient CTCs capture and reagent-less monitoring of immune checkpoint PD-L1 expression on CTCs with non-small cell lung cancer patients
Yuping Liu, Beibei Zhang, Xueyuan Wu, et al.
Biosensors and Bioelectronics (2025) Vol. 275, pp. 117236-117236
Closed Access | Times Cited: 1
Yuping Liu, Beibei Zhang, Xueyuan Wu, et al.
Biosensors and Bioelectronics (2025) Vol. 275, pp. 117236-117236
Closed Access | Times Cited: 1
Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity
Dianying Zhang, Jingjing Zhao, Yujing Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Dianying Zhang, Jingjing Zhao, Yujing Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer
Xin Zhou, Yan Shi, Xiaopan Ma, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2025)
Closed Access
Xin Zhou, Yan Shi, Xiaopan Ma, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2025)
Closed Access
Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
Meifeng Luo, Huiting Wei, Moqin Qiu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Meifeng Luo, Huiting Wei, Moqin Qiu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Immunotherapy-induced microsatellite instability status shift in recurrent perihilar cholangiocarcinoma: A case report
Hailing Yu, Tan Deng, Hongbing Liu
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Hailing Yu, Tan Deng, Hongbing Liu
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Multi-cohort study in gastric cancer to develop CT-based radiomic models to predict pathological response to neoadjuvant immunotherapy
Ze‐Ning Huang, Haoxiang Zhang, Yuqin Sun, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Ze‐Ning Huang, Haoxiang Zhang, Yuqin Sun, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Innovative, early-phase clinical trials of drug–radiotherapy combinations
Antonin Lévy, Christophe Massard, Stefan Michiels, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 4, pp. e190-e202
Closed Access
Antonin Lévy, Christophe Massard, Stefan Michiels, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 4, pp. e190-e202
Closed Access
Impact of Platinum-Based Chemotherapy and CTLA-4 Inhibition on Acquired Resistance to First-Line Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer: A Systematic Review and Reconstructed Individual Patient Data Analysis
Sara Oresti, Fabio Salomone, A. Nuccio, et al.
(2025)
Closed Access
Sara Oresti, Fabio Salomone, A. Nuccio, et al.
(2025)
Closed Access
Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR ‐TKI Treatment: A Retrospective Cohort Study
Yanjun Su, Shu‐Farn Tey, Chung‐Ta Lee, et al.
The Kaohsiung Journal of Medical Sciences (2025)
Open Access
Yanjun Su, Shu‐Farn Tey, Chung‐Ta Lee, et al.
The Kaohsiung Journal of Medical Sciences (2025)
Open Access
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
Alessandro Di Federico, Lingzhi Hong, Arielle Elkrief, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 1
Alessandro Di Federico, Lingzhi Hong, Arielle Elkrief, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 1
Lipidomics reveals biomarkers of the efficacy of first-line ICIs therapy combined with chemotherapy in NSCLC
Jia Yu, Hanyan Xu, Fen Xiong, et al.
Research Square (Research Square) (2024)
Closed Access
Jia Yu, Hanyan Xu, Fen Xiong, et al.
Research Square (Research Square) (2024)
Closed Access
